MRD-driven treatment paradigm for newly diagnosed transplant eligible multiple myeloma patients

Minimal residual disease in myeloma by flow cytometry: independent prediction of survival benefit per log reduction

(2015) A. C. Rawstron et al.   BLOOD

Minimal residual disease testing after stem cell transplantation for multiple myeloma

(2015) A M Sherrod et al.   BONE MARROW TRANSPLANTATION

Better therapy requires better response evaluation: Paving the way for minimal residual disease testing for every myeloma patient

(2015) Ola Landgren et al.   CYTOMETRY PART B-CLINICAL CYTOMETRY

Minimal residual disease in multiple myeloma: bringing the bench to the bedside

(2015) Sham Mailankody et al.   Nature Reviews Clinical Oncology

Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma

(2015) Neha Korde et al.   JAMA Oncology

Minimal Residual Disease Assessed by Multiparameter Flow Cytometry in Multiple Myeloma: Impact on Outcome in the Medical Research Council Myeloma IX Study

(2013) Andy C. Rawstron et al.   JOURNAL OF CLINICAL ONCOLOGY

High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma

(2011) B. Paiva et al.   BLOOD

Comparison of Immunofixation, Serum Free Light Chain, and Immunophenotyping for Response Evaluation and Prognostication in Multiple Myeloma

(2011) Bruno Paiva et al.   JOURNAL OF CLINICAL ONCOLOGY

Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation

(2008) B. Paiva et al.   BLOOD